Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Short Interest Update

Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Get Free Report) was the recipient of a large decline in short interest in May. As of May 15th, there was short interest totalling 589,500 shares, a decline of 16.1% from the April 30th total of 702,500 shares. Based on an average daily volume of 263,300 shares, the short-interest ratio is currently 2.2 days. Currently, 2.7% of the shares of the stock are short sold.

Institutional Investors Weigh In On Eton Pharmaceuticals

Large investors have recently added to or reduced their stakes in the stock. AlphaQuest LLC purchased a new stake in shares of Eton Pharmaceuticals during the first quarter valued at $53,000. Tower Research Capital LLC TRC bought a new stake in shares of Eton Pharmaceuticals in the 4th quarter valued at about $86,000. Quantbot Technologies LP acquired a new stake in Eton Pharmaceuticals in the first quarter valued at approximately $101,000. Jefferies Financial Group Inc. purchased a new stake in shares of Eton Pharmaceuticals during the 4th quarter valued at $133,000. Finally, Point72 Asia Singapore Pte. Ltd. boosted its position in shares of Eton Pharmaceuticals by 18.3% in the 4th quarter. Point72 Asia Singapore Pte. Ltd. now owns 10,561 shares of the company's stock worth $141,000 after purchasing an additional 1,634 shares in the last quarter. 27.86% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have commented on the stock. B. Riley reiterated a "buy" rating and set a $26.00 price target (up from $24.00) on shares of Eton Pharmaceuticals in a research report on Friday, May 16th. Craig Hallum increased their price objective on Eton Pharmaceuticals from $26.00 to $28.00 and gave the stock a "buy" rating in a report on Wednesday, May 14th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $35.00 price target (up from $33.00) on shares of Eton Pharmaceuticals in a research note on Thursday, May 29th.

Eton Pharmaceuticals Stock Performance

Shares of Eton Pharmaceuticals stock traded up $0.50 on Thursday, hitting $17.45. 306,094 shares of the company's stock were exchanged, compared to its average volume of 305,616. Eton Pharmaceuticals has a 1 year low of $3.18 and a 1 year high of $21.48. The stock has a market capitalization of $467.84 million, a PE ratio of -79.45 and a beta of 1.22. The company has a 50-day simple moving average of $16.08 and a 200-day simple moving average of $14.80.

Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) last released its quarterly earnings data on Tuesday, May 13th. The company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.09 by ($0.02). Eton Pharmaceuticals had a negative net margin of 15.81% and a negative return on equity of 36.29%. The company had revenue of $17.28 million for the quarter, compared to the consensus estimate of $14.33 million. On average, analysts expect that Eton Pharmaceuticals will post -0.14 EPS for the current fiscal year.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.